📰 GPCR Weekly News - January 2 to 8, 2023

Hello Readers👋,

We're excited to share our weekly newsletter with you. Keep up-to-date with the latest research and advancements in the field with our convenient, weekly news delivered to your inbox. You can always adjust your email preferences in your account settings.

Below is your Classified GPCR News at a glance for January 2nd to January 8th, 2023.

GPCR Activation and Signaling

• Signal Transduction and Gene Regulation in the Endothelium.

• Pharmacological Profiling of a Brugia malayi Muscarinic Acetylcholine Receptor as a Putative Antiparasitic Target.

• GPCR Signaling Measurement and Drug Profiling with an Automated Live-Cell Microscopy System.

GPCR Binders, Drugs, and more

• Cytotoxicity-related effects of imidazolium and chlorinated bispyridinium oximes in SH-SY5Y cells.

GPCRs in Neuroscience

• Filamin A organizes γ‑aminobutyric acid type B receptors at the plasma membrane.

GPCRs in Oncology and Immunology

• Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway.

Methods & Updates in GPCR Research

• Small Molecule Tools to Study Cellular Target Engagement for the Intracellular Allosteric Binding Site of GPCRs.

Structural and Molecular Insights into GPCR Function

• Structural and functional analyses of a GPCR-inhibited ion channel TRPM3.

Industry News

• Arcoscreen selected by START Lausanne to pitch at the START Global summit on the 23-24th March 2023.

• Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration

• Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

• Crinetics Pharmaceuticals To Present Corporate And Clinical Update At 41st Annual J.P. Morgan Healthcare Conference

• Neurocrine Biosciences, Inc.'s Director Stephen A. Sherwin Sells 30,000 Shares

• STALICLA signs agreement with Novartis on neurodevelopmental disorders
  

Call for GPCR Papers

• GPCRs: Signal Transduction. Deadline February 12, 2023

• Current Technologies To Understand G-Protein-Coupled Receptor Molecular Pharmacology. Deadline January 30, 2023.

GPCR Events, Meetings, and Webinars

• 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston.

• 2nd ERNEST Training School – February 20th to March 3rd.

• GEM2023 (14-17 March 2023).

• 8th and final ERNEST Meeting May 3-7, 2023 in Crete.

• The Illuminating the Understudied Druggable Proteome Conference. June 4-8,2023.

• 2023 Molecular Pharmacology (GRS) Seminar GRC. June 10 - 11.

• Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. June 11-16, 2023.

• 19th World Congress of Basic & Clinical Pharmacology 2023. July 2 - 7.

GPCR Jobs

• Biotechnology and Biological Sciences Doctoral Training Programme

• Senior QM Manager

• Director of Molecular Pharmacology, Discovery Biology

• Staff Scientist/Senior Staff Scientist, Disease Biology and Translational Sciences

• Senior Scientist, Drug Metabolism and Pharmacokinetics

• PhD Opportunity - Investigation Of The Role Of The Formyl Peptide Receptor 2 In Diabetic Retinopathy

• PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery
  

Explore Dr. GPCR Ecosystem